Proactive Investors - Run By Investors For Investors

Orgenesis CEO says companies looking for ways to get costs of medicine down

US officials and lawmakers have criticized drug makers for their expensive medications
Orgenesis is a manufacturer, service provider and developer of advanced cell therapies.

The chief executive of Orgenesis Inc (NASDAQ:ORGS) said on Friday biotech companies are looking for ways to lower the cost of drugs.

"I think industry is dedicated to that. We certainly have a pivotal role I think in that space," Vered Caplan, the CEO of the company, said in an interview on Yahoo's Midday Movers..

She added: "If you look at the hospitals that are involved, the research institutes, they are all looking for a way from the science perspective how do we get the costs down."

US officials have criticized drug makers for the expensive drugs they make.

Shares of Orgenesis closed on Friday up 1.26% to $6.45.

READ: Orgenesis' cell therapy development business pushes into the US

Caplan said there is a technology issue where investments must be made in the development of cutting-edge drugs.

"Let us look at the drugs we make. These are the next-generation," she said.

She said women are "very well accepted" when asked about the fact that there are very few women in the top ranks of companies in the country.

Orgenesis is a manufacturer, service provider and developer of advanced cell therapies.

The company is based in Germantown, Maryland.

Reporting by Rene Pastor, contactable on [email protected]

View full ORGS profile View Profile

Orgenesis Timeline

Related Articles

Lung X-Ray
October 22 2018
In its recent half-year results, the medical research investor recorded a loss after tax of £4.6mln in the six months ended June 30, less than the £5.2mln loss a year ago
scientist in lab
December 18 2018
VAL401 is ValiRx’s most advanced compound, with earlier trial results suggesting it can improve quality of life and chances of survival of lung cancer patients
blood samples in test tubes
October 25 2018
The NYSE-listed company has designed a routine blood test to screen for colorectal and prostate cancers that reduces the need for more invasive colonoscopies and biopsies
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use